ID: ALA348270

Max Phase: Preclinical

Molecular Formula: C19H17NO3

Molecular Weight: 307.35

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(O)C1=C(C(=O)Nc2ccc(-c3ccccc3)cc2)CCC1

Standard InChI:  InChI=1S/C19H17NO3/c21-18(16-7-4-8-17(16)19(22)23)20-15-11-9-14(10-12-15)13-5-2-1-3-6-13/h1-3,5-6,9-12H,4,7-8H2,(H,20,21)(H,22,23)

Standard InChI Key:  KKMNLDWJDASMGY-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 307.35

Molecular Weight (Monoisotopic): 307.1208

AlogP: 3.86

#Rotatable Bonds: 4

Polar Surface Area: 66.40

Molecular Species: ACID

HBA: 2

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.31

CX Basic pKa:

CX LogP: 3.81

CX LogD: 0.39

Aromatic Rings: 2

Heavy Atoms: 23

QED Weighted: 0.90

Np Likeness Score: -0.50

References

1. Leban J, Saeb W, Garcia G, Baumgartner R, Kramer B..  (2004)  Discovery of a novel series of DHODH inhibitors by a docking procedure and QSAR refinement.,  14  (1): [PMID:14684297] [10.1016/j.bmcl.2003.10.021]

2. Leban J, Kralik M, Mies J, Gassen M, Tentschert K, Baumgartner R..  (2005)  SAR, species specificity, and cellular activity of cyclopentene dicarboxylic acid amides as DHODH inhibitors.,  15  (21): [PMID:16143532] [10.1016/j.bmcl.2005.07.053]

3. Leban J, Kralik M, Mies J, Baumgartner R, Gassen M, Tasler S..  (2006)  Biphenyl-4-ylcarbamoyl thiophene carboxylic acids as potent DHODH inhibitors.,  16  (2): [PMID:16246558] [10.1016/j.bmcl.2005.10.011]

4. Mancini RS, Barden CJ, Weaver DF, Reed MA..  (2021)  Furazans in Medicinal Chemistry.,  64  (4.0): [PMID:33569941] [10.1021/acs.jmedchem.0c01901]

Source

Source(1):

• Scientific Literature